Close Menu

Ebola

Tekmira Pharmaceuticals this week announced that it has added hepatitis B to its pipeline, and that it anticipates filing an investigational new drug application for the program in 2014.

Officials from Tekmira Pharmaceuticals this week updated the company’s research and development efforts, stating that the company continues to expect its lead drug candidate, the cancer therapy TKM-PLK1, to move into phase II testing later this year.

Tekmira Pharmaceuticals this week announced that its contract with the US Department of Defense to develop an RNAi-based Ebola virus drug has been modified to allow for improvements made to the company’s drug formulation and manufacturing technologies.

Tekmira Pharmaceuticals this week said that it has completed the main part of a phase I study of the siRNA-based cancer drug TKM-PLK1, and is slated to present the trial’s results in two weeks at the American Association for Cancer Research’s annual meeting.

Emboldened by a $65 million payout from Alnylam Pharmaceuticals as part of a litigation settlement, Tekmira Pharmaceuticals this week offered a pipeline update that includes the “aggressive advancement” of a number of drug candidates.

Tekmira Pharmaceuticals this week announced that the US Department of Defense has decided to continue its contract with the company to develop an RNAi-based treatment for Ebola virus infection.

Tekmira Pharmaceuticals said last week that the US Department of Defense has extended the temporary stop-work order it recently imposed on its partnership with the company to develop an RNAi-based treatment for Ebola virus infection.

Tekmira Pharmaceuticals this week released interim results from an ongoing phase I trial of its siRNA-based cancer treatment TKM-PLK1, which showed the drug to be well tolerated despite an “aggressive” dosing regimen, with some signs of clinical activity.

This article has been updated to include additional stock information and analyst comment.

Pages

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.